Myogen to Present at the Leerink Swann Vascular Modlulation Conference
19 Avril 2006 - 10:00PM
Business Wire
Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on
the discovery, development and commercialization of small molecule
therapeutics for the treatment of cardiovascular disorders, today
announced that J. William Freytag, President and CEO, will
participate in the Leerink Swann Vascular Modulation Conference to
be held April 28, 2006, in Boston, Massachusetts. The Company's
presentation will take place at 3:00 p.m. (Eastern) on Friday,
April 28, 2006. There will be a live webcast of the presentation,
which will be accessible through a link posted on the investor
relations section of the Myogen website at
http://investor.myogen.com/. The webcast will be available for
replay on Myogen's website through May 17, 2006. Myogen currently
has two product candidates in late-stage clinical development:
ambrisentan for the treatment of patients with pulmonary arterial
hypertension and darusentan for the treatment of patients with
resistant hypertension. Myogen and GlaxoSmithKline have entered
into a global PAH partnership in which Myogen has distribution and
marketing rights to GlaxoSmithKline's Flolan (epoprostenol sodium)
in the United States for the treatment of PAH and GlaxoSmithKline
has licensed ambrisentan from Myogen for all territories outside of
the United States. Myogen also conducts a target and drug discovery
research program focused on the development of disease-modifying
drugs for the treatment of chronic heart failure and related
cardiovascular disorders. Please visit Myogen's website at
www.myogen.com. Safe Harbor Statement The anticipated presentation
will contain forward-looking statements that involve significant
risks and uncertainties, including those to be discussed in the
presentation and others that can be found in the "Risk Factors"
section of Myogen's Form 10-K for the year ended December 31, 2005,
and Myogen's periodic reports on Form 10-Q and Form 8-K. Myogen
does not undertake any obligation to update any forward-looking
statements contained in the anticipated presentation as a result of
new information, future events or otherwise. The company cautions
investors not to place undue reliance on the forward-looking
statements contained in this press release or the presentation. No
forward-looking statement can be guaranteed and actual events and
results may differ materially from those projected.
Myogen (NASDAQ:MYOG)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Myogen (NASDAQ:MYOG)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Myogen (NASDAQ): 0 recent articles
Plus d'articles sur Myogen, Inc.